• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,140
109
75
71
68

COUNTRY

70
22
16
10
9

CATEGORIES

  • 574
  • 118
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

964
1,166
1,646
2,949

PUBLISHED

141
220
640
2,949

PRODUCT TYPE

2,377
494
68
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Hematological Cancers Drug Pathway Analyzer 2014 Hematological Cancers Drug Pathway Analyzer 2014 - Product Thumbnail Image

Hematological Cancers Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 672 targeted molecular therapies known to affect more than 256 specific intracellular signaling pathways...

July 2014
FROM
Colorectal Cancer Drug Pathway Analyzer 2014 Colorectal Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Colorectal Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 375 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways...

July 2014
FROM
Gastrointestinal Cancer Drug Pathway Analyzer 2014 Gastrointestinal Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Gastrointestinal Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 185 targeted molecular therapies known to affect more than 237 specific intracellular signaling pathways...

July 2014
FROM
Ovarian Cancer Drug Pathway Analyzer 2014 Ovarian Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Ovarian Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 320 targeted molecular therapies known to affect more than 250 specific intracellular signaling pathways...

July 2014
FROM
Prostate Cancer Drug Pathway Analyzer 2014 Prostate Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Prostate Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 386 targeted molecular therapies known to affect more than 244 specific intracellular signaling pathways...

July 2014
FROM
Peptides in Oncology: Drug Pathway Analyzer 2014 Peptides in Oncology: Drug Pathway Analyzer 2014 - Product Thumbnail Image

Peptides in Oncology: Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 188 peptide drugs known to affect more than 216 specific intracellular signaling pathways for the treatment...

July 2014
FROM
MicroRNAs in Cancer Drug Pipeline Update 2014 MicroRNAs in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

MicroRNAs in Cancer Drug Pipeline Update 2014

The hot entry of microRNA (miRNA) targeting drugs in oncology may come to revolutionize how we in the near future can launch a highly tumor-specific, multi-targeted attack with minimal toxicities either...

July 2014
FROM
IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014 IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014

The IL-2 signaling pathway activates the Ras/MAPK, JAK/Stat and PI 3-kinase/Akt signaling modules. There are today 244 companies plus partners developing 370 IL-2 pathway targeting drugs in 1307 developmental...

July 2014
FROM
T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

T Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

Stimulation of the T cell receptor leads to the activation of NFkB and NFAT signaling modules which play a key role in T cell receptor signaling. There are today 246 companies plus partners developing...

July 2014
FROM
Notch Signaling Pathway in Oncology Drug Pipeline Update 2014 Notch Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Notch Signaling Pathway in Oncology Drug Pipeline Update 2014

Aberrant Notch signaling has been linked to a number of malignancies including leukemias, lymphomas and carcinomas of the breast, skin, lung, cervix and kidneys. There are today 252 companies plus partners...

July 2014
FROM
Oncology Drug Pathway Analyzer (Premium Version) Oncology Drug Pathway Analyzer (Premium Version) - Product Thumbnail Image

Oncology Drug Pathway Analyzer (Premium Version)

EXTRA: Free online updates for a year Get instant, interactive pathway modeling on more than 3,500 cancer drugs across more than 100 different cancer types. Drug targets and their pathways are the...

July 2014
FROM
Cell Cycle Targeting in Cancer Drug Pipeline Update 2014 Cell Cycle Targeting in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Cell Cycle Targeting in Cancer Drug Pipeline Update 2014

There are today 144 companies plus partners developing 164 targeting the cell cycle drugs in 552 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number...

July 2014
FROM
Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2014 Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2014

Fc epsilon RI-mediated signaling pathways in mast cells are initiated by the interaction of antigen (Ag) with IgE bound to the extracellular domain of the alpha chain of Fc epsilon RI. The activation...

July 2014
FROM
Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014 Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Interfering With Cytokine-Cytokine Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014

Cytokines are soluble extracellular proteins or glycoproteins that are crucial intercellular regulators and mobilizers of cells engaged in innate as well as adaptive inflammatory host defenses, cell...

July 2014
FROM
Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014 Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014

The extracellular matrix (ECM) consists of a complex mixture of structural and functional macromolecules and serves an important role in tissue and organ morphogenesis and in the maintenance of cell...

July 2014
FROM
mTOR Signaling Pathway in Oncology Drug Pipeline Update 2014 mTOR Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

mTOR Signaling Pathway in Oncology Drug Pipeline Update 2014

The mammalian target of rapamycin (mTOR) is an intracellular kinase that controls the production of proteins through its regulation of translational machinery. mTOR-activated proteins promote several...

July 2014
FROM
Cancer Drugs in the FDA Fast Lane Drug Pipeline Update 2014 Cancer Drugs in the FDA Fast Lane Drug Pipeline Update 2014 - Product Thumbnail Image

Cancer Drugs in the FDA Fast Lane Drug Pipeline Update 2014

The US Food and Drug Administration (FDA) has throughout the last decades added four major ways it can speed up the market approval of new drugs, ranging from Fast track (1988), Accelerated approval...

July 2014
FROM
Liver Cancer Drug Pathway Analyzer 2014 Liver Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Liver Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 176 targeted molecular therapies known to affect more than 231 specific intracellular signaling pathways...

July 2014
FROM
Neuroendocrine Tumors Drug Pathway Analyzer 2014 Neuroendocrine Tumors Drug Pathway Analyzer 2014 - Product Thumbnail Image

Neuroendocrine Tumors Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 58 targeted molecular therapies known to affect more than 214 specific intracellular signaling pathways...

July 2014
FROM
Proteins in Oncology: Drug Pathway Analyzer 2014 Proteins in Oncology: Drug Pathway Analyzer 2014 - Product Thumbnail Image

Proteins in Oncology: Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 353 protein drugs known to affect more than 202 specific intracellular signaling pathways for the treatment...

July 2014
FROM
Loading Indicator

Our Clients

Our clients' logos